OBJECTIVE: To investigate the relationships between several health outcomes in ankylosing spondylitis (AS). METHODS: Baseline pretreatment data from 214 patients with AS participating in the AS Study for the Evaluation of Recombinant Infliximab Therapy were analysed. Measures of health-related quality of life (HRQoL) and physical function were used as dependent variables in linear regression analysis. Associations between HRQoL (36-Item Short Form (SF-36)), physical function, clinical disease activity, spinal mobility, structural damage, MRI inflammation, disease duration, age, gender, body mass index and HLA-B27 were explored. Univariate associations were retested in multivariate models. The robustness of the models was evaluated by sensitivity analyses. RESULTS: The physical component of SF-36 was independently associated with measures of physical function and disease activity (adjusted R(2) (adjR(2))=0.39-0.40). The mental component of SF-36 was independently associated with physical function (adjR(2)=0.07). Physical function was independently associated with measures of spinal mobility and disease activity (adjR(2)=0.39-0.45). Spinal mobility was hierarchically shown to be an intermediate variable between structural damage and physical function, while physical function was shown to be intermediate between spinal mobility and the physical component of SF-36. CONCLUSION: According to the proposed stratified model for health outcomes in AS, HRQoL is determined by physical function and disease activity, physical function is determined by spinal mobility and disease activity, and spinal mobility is determined by structural damage and inflammation of the spine. As more is learnt about how to measure AS, knowledge about the disease improves and better decisions can be made on the assessment and treatment of this disease.
RCT Entities:
OBJECTIVE: To investigate the relationships between several health outcomes in ankylosing spondylitis (AS). METHODS: Baseline pretreatment data from 214 patients with AS participating in the AS Study for the Evaluation of Recombinant Infliximab Therapy were analysed. Measures of health-related quality of life (HRQoL) and physical function were used as dependent variables in linear regression analysis. Associations between HRQoL (36-Item Short Form (SF-36)), physical function, clinical disease activity, spinal mobility, structural damage, MRI inflammation, disease duration, age, gender, body mass index and HLA-B27 were explored. Univariate associations were retested in multivariate models. The robustness of the models was evaluated by sensitivity analyses. RESULTS: The physical component of SF-36 was independently associated with measures of physical function and disease activity (adjusted R(2) (adjR(2))=0.39-0.40). The mental component of SF-36 was independently associated with physical function (adjR(2)=0.07). Physical function was independently associated with measures of spinal mobility and disease activity (adjR(2)=0.39-0.45). Spinal mobility was hierarchically shown to be an intermediate variable between structural damage and physical function, while physical function was shown to be intermediate between spinal mobility and the physical component of SF-36. CONCLUSION: According to the proposed stratified model for health outcomes in AS, HRQoL is determined by physical function and disease activity, physical function is determined by spinal mobility and disease activity, and spinal mobility is determined by structural damage and inflammation of the spine. As more is learnt about how to measure AS, knowledge about the disease improves and better decisions can be made on the assessment and treatment of this disease.
Authors: Bora Nam; Bon San Koo; Seoung Wan Nam; Ji-Hui Shin; Yoonah Song; Soo-Kyung Cho; Yoon-Kyoung Sung; Tae-Hwan Kim Journal: Qual Life Res Date: 2021-03-10 Impact factor: 4.147
Authors: U Kiltz; D van der Heijde; A Boonen; A Cieza; G Stucki; M A Khan; W P Maksymowych; H Marzo-Ortega; J Reveille; S Stebbings; C Bostan; J Braun Journal: Ann Rheum Dis Date: 2014-01-07 Impact factor: 19.103
Authors: Siddharth Bethi; Abhijit Dasgupta; Michael H Weisman; Thomas J Learch; Lianne S Gensler; John C Davis; John D Reveille; Michael M Ward Journal: Arthritis Care Res (Hoboken) Date: 2013-04 Impact factor: 4.794
Authors: Féline P B Kroon; Lennart R A van der Burg; Sofia Ramiro; Robert B M Landewé; Rachelle Buchbinder; Louise Falzon; Désirée van der Heijde Journal: Cochrane Database Syst Rev Date: 2015-07-17
Authors: Josef S Smolen; Jürgen Braun; Maxime Dougados; Paul Emery; Oliver Fitzgerald; Philip Helliwell; Arthur Kavanaugh; Tore K Kvien; Robert Landewé; Thomas Luger; Philip Mease; Ignazio Olivieri; John Reveille; Christopher Ritchlin; Martin Rudwaleit; Monika Schoels; Joachim Sieper; Martinus de Wit; Xenofon Baraliakos; Neil Betteridge; Ruben Burgos-Vargas; Eduardo Collantes-Estevez; Atul Deodhar; Dirk Elewaut; Laure Gossec; Merryn Jongkees; Mara Maccarone; Kurt Redlich; Filip van den Bosch; James Cheng-Chung Wei; Kevin Winthrop; Désirée van der Heijde Journal: Ann Rheum Dis Date: 2013-06-08 Impact factor: 19.103
Authors: Jun Won Park; Hyun Mi Kwon; Jin Kyun Park; Ja-Young Choi; Eun Bong Lee; Yeong Wook Song; Eun Young Lee Journal: PLoS One Date: 2016-12-29 Impact factor: 3.240
Authors: U Kiltz; D van der Heijde; A Boonen; W Bautista-Molano; R Burgos-Vargas; P Chiowchanwisawakit; T Duruoz; B El-Zorkany; I Essers; I Gaydukova; P Géher; L Gossec; S Grazio; J Gu; M A Khan; T J Kim; W P Maksymowych; H Marzo-Ortega; V Navarro-Compán; I Olivieri; D Patrikos; F M Pimentel-Santos; M Schirmer; F van den Bosch; U Weber; J Zochling; J Braun Journal: RMD Open Date: 2016-10-04